All Articles

As Malaysia's economic boom fuels urban traffic pollution, a new market for in-home health tech is emerging. Can companies like Levoit turn this risk into a strategic win?

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Broadway star Morgan Dudley returns to the tech platform that discovered her. Can her insider role help Stargaze win the high-stakes talent-tech race?

A deep dive into 22 Fulton Street, where complex finance, green design, and affordable housing converge to reshape Newark's skyline and its community.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

GoldMining Inc. renews its flexible financing tool to tap the market. We analyze the strategy, the projects at stake, and the dilution dilemma for investors.

With its finances in distress, Netcapital bets its future on blockchain and a new CEO. Can a turnaround specialist navigate the crypto frontier?

Suburban Propane is refinancing its debt, extending it to 2035. Is this a savvy move to fund its green energy transition or a costly bet on stability?

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

Toro's acquisition of Tornado isn't just about new machinery; it's a calculated move to capture the booming, safety-critical underground excavation market.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Global Ship Lease's steady dividend is more than investor news; it reveals deep insights into containership market health and strategic resilience.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

A junior miner's historic regulatory win in Oregon could set a new precedent for resource development, balancing economic promise with environmental rigor.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

Latham Group hires building products veteran Sean Gadd to lead its next wave of growth. Can a playbook that dominated fiber cement convert the pool industry?